• PD 173074: FGFR1 Assay Workflows

  2026-08-26

  PD 173074 combines nanomolar FGFR1 activity with useful VEGFR2 inhibition for dissecting oncogenic signaling, angiogenesis, and resistance phenotypes. This workflow-led guide connects pathway pharmacology with MIR9-driven acute lymphoblastic leukaemia biology and practical assay troubleshooting.

• Puromycin aminonucleoside: Renal Injury Workflow

  2026-08-26

  Build reproducible podocyte injury models with a workflow that connects reagent preparation, pH-sensitive uptake, structural phenotyping, and proteinuria monitoring. This guide also shows how the reference study’s orthogonal biomarker strategy can improve interpretation without overextending glioma findings into renal biology.

• RESTRICT-seq Maps KAT6A in SCC Resistance

  2026-08-25

  The bioRxiv preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy that separates genetic dependencies involved in establishing squamous cell carcinoma resistance from those required to maintain it. Its prioritization of KAT6A supports a state-aware view of chromatin regulation and provides a rationale for orthogonal validation in cancer biology research.

• Cediranib (AZD2171) in Translational Cancer Research

  2026-08-25

  Cediranib (AZD2171) is more than a potent angiogenesis inhibitor: it is a mechanistic probe for separating VEGFR pathway suppression, endothelial responses, proliferative arrest, and cell death. This thought-leadership guide connects its kinase profile with rigorous in vitro assay design and translational interpretation.

• Tivozanib (AV-951) Assay Design Guide

  2026-08-24

  Build more informative VEGFR-focused cancer assays with Tivozanib (AV-951), from concentration preparation through time-resolved viability and death measurements. This workflow separates growth arrest from cell killing, improving interpretation of renal cell carcinoma and combination-treatment studies.

• Coumestrol Workflows for RA Ferroptosis Research

  2026-08-24

  Coumestrol offers a practical bridge between estrogen receptor biology and ferroptosis-focused rheumatoid arthritis research. This workflow translates RA-FLS findings into reproducible dosing, orthogonal readouts, mechanism validation, and nuclear receptor-aware troubleshooting.

• Pazopanib Hydrochloride In Vitro Workflow

  2026-08-23

  Build more informative oncology assays with Pazopanib Hydrochloride by separating growth arrest from true cell killing. This workflow combines dose-response design, angiogenesis-focused models, paired viability metrics, and practical troubleshooting for renal cell carcinoma and soft tissue sarcoma research.

• Chronic Cabozantinib Remodeling in RCC

  2026-08-22

  A 2026 study used quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. It found persistent suppression of activating MET phosphorylation alongside selective adhesion-, stress-, and MAPK/AP-1-associated remodeling, with context-dependent changes in migration and invasion.

• AP20187: Chemical Inducer of Dimerization

  2026-08-22

  AP20187 enables timed activation of engineered fusion proteins for conditional gene expression, regulated cell therapy, and metabolic studies. Its value is greatest when researchers pair a tunable dimerization trigger with orthogonal controls, quantitative reporters, and careful handling of stock solutions.

• AZD3463 for ALK-Driven Cancer Research

  2026-08-21

  AZD3463 is an ALK/IGF1R inhibitor designed for mechanism-focused neuroblastoma studies, from mutation-aware viability assays to pathway and combination-treatment workflows. This guide emphasizes reproducible dosing, solvent control, apoptosis and autophagy readouts, and careful interpretation when extending pathway insights across cancer models.

• ERCC1 Deficiency, p53, and Cisplatin Response

  2026-08-20

  Heyza et al. show that ERCC1 loss does not predict cisplatin sensitivity independently of tumor context: p53 status strongly determines apoptosis, viability, and interstrand-crosslink repair behavior. The study combines CRISPR-engineered lung cancer models with patient survival analyses, providing a framework for interpreting ERCC1 as a platinum-response biomarker.

• PDK4-IN-1 hydrochloride for Metabolic Studies

  2026-08-20

  PDK4-IN-1 hydrochloride gives researchers a selective way to connect PDH activation with mitochondrial energy metabolism, glycolysis, and TCA-cycle behavior. This practical guide covers assay setup, translational workflows, comparative controls, and troubleshooting for metabolic, cardiac, and tumor models.

• How Near-Death Cells Seed Metastatic States

  2026-08-19

  Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving impending cell death can acquire stable prometastatic states called PAMEs. Their work links ER stress, PERK–CHOP signaling, nuclear reprogramming, stemness, and cytokine-mediated recruitment of neighboring PIM cells to the origin of metastases.

• PD 173074 for FGFR1 and LUAD Assays

  2026-08-19

  PD 173074 provides a practical pharmacological probe for testing FGFR1 dependence, VEGFR2-linked angiogenesis, and drug-response phenotypes in lung adenocarcinoma models. This workflow combines CENPO-guided patient biology with target-engagement assays, dose design, and troubleshooting strategies that distinguish pathway suppression from nonspecific toxicity.

• Anlotinib for IADSRCT: Case and Literature Review

  2026-08-18

  This case report describes the first reported clinical use of anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor, with radiographic lymph-node reduction and tolerable toxicity after prior surgery and chemotherapy. Its main significance is hypothesis-generating: it connects the anti-angiogenic, multi-target activity of anlotinib with a rare tumor lacking standardized systemic treatment, while also highlighting the limits of single-patient evidence.

7498 records 8/500 page Previous Next First page 上5页 678910 下5页 Last page